Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CASP6 | P55212 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 8/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CTSV | O60911 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6369270 | 0.94 | SMN1; SMN2 (0.45) | ALDH1A1KMT2AMEN1POLBCASP6 | |
| SCHEMBL11270404 | 0.86 | ALDH1A1 (0.42) | ALDH1A1KMT2AMEN1POLBCASP6 | |
| SCHEMBL31159941 | 0.82 | ALDH1A1 (0.48) | ALDH1A1KMT2AMEN1POLBMAPT | |
| SCHEMBL1056621 | 0.82 | ALDH1A1 (0.48) | ALDH1A1KMT2AMEN1POLBMAPT | |
| SCHEMBL727921 | 0.80 | PARP1 (0.44) | ALDH1A1KMT2AMEN1POLBCASP6 | |
| SCHEMBL7261988 | 0.80 | L3MBTL1 (0.50) | ALDH1A1KMT2AMEN1POLBMAPT | |
| SCHEMBL6369097 | 0.77 | KMT2A (0.49) | ALDH1A1KMT2AMEN1MAPTSMN1; SMN2 | |
| SCHEMBL6369597 | 0.77 | ALDH1A1 (0.43) | ALDH1A1KMT2AMEN1MAPTSMN1; SMN2 | |
| SCHEMBL11270948 | 0.77 | L3MBTL1 (0.56) | ALDH1A1MAPTSMN1; SMN2LMNA | |
| SCHEMBL9173956 | 0.77 | KMT2A (0.41) | ALDH1A1KMT2AMEN1POLBCASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8334304-B2 | Aminosulfonyl substituted 4-(aminomethyl)-piperidine benzamides as 5HT4-antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-12-18 | — | — | US | disclosed |
| US-8334304-B2 | Aminosulfonyl substituted 4-(aminomethyl)-piperidine benzamides as 5HT4-antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-12-18 | — | — | US | disclosed |
| US-20100087483-A1 | Aminosulfonyl Substituted 4-(Aminomethyl)-Piperidine Benzamides As 5HT 4-Antagonists | BOSMANS JEAN-PAUL RENE MARIE ANDRE | 2010-04-08 | — | — | US | disclosed |
| US-20100087483-A1 | Aminosulfonyl Substituted 4-(Aminomethyl)-Piperidine Benzamides As 5HT 4-Antagonists | BOSMANS JEAN-PAUL RENE MARIE ANDRE | 2010-04-08 | — | — | US | disclosed |
| US-7638535-B2 | (3S)-trans)-8-methyl-3,4-dihydro-2H-benzo[b][1,4]dioxepine-6-carboxylic acid [3-hydroxy-1-(3-methoxy-propyl)-piperidin-4-ylmethyl]-amide; hypermotility, irritable bowel syndrome, constipation or diarrhea predominant IDS, pain and non-pain predominant IBS and bowel hypersensitivity | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-12-29 | — | — | US | disclosed |
| US-7638535-B2 | (3S)-trans)-8-methyl-3,4-dihydro-2H-benzo[b][1,4]dioxepine-6-carboxylic acid [3-hydroxy-1-(3-methoxy-propyl)-piperidin-4-ylmethyl]-amide; hypermotility, irritable bowel syndrome, constipation or diarrhea predominant IDS, pain and non-pain predominant IBS and bowel hypersensitivity | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-12-29 | — | — | US | disclosed |
| US-20090076274-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED | 2009-03-19 | — | — | US | disclosed |
| US-20060264429-A1 | Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders | GLAXO GROUP LIMITED (GB) | 2006-11-23 | — | — | US | disclosed |
| EP-1562917-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004046124-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED (GB) | 2004-06-03 | — | — | WO | disclosed |
| EP-0724580-A1 | BENZANILIDE DERIVATIVES AS 5HT-1D RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1996-08-07 | — | — | EP | disclosed |
| WO-1995011243-A1 | BENZANILIDE DERIVATIVES AS 5HT-1D RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-04-27 | — | — | WO | disclosed |
| US-4323503-A | PSYCHOFUNCTION PROPERTIES SUCH AS ANXIOLYTIC OR PSYCHOSTIMULANT | SOCIETE D'ETUDES SCIENTIFIQUES ET INDUSTRIELLES DE L'ILE-DE-FRANCE (FR) | 1982-04-06 | — | — | US | disclosed |
| US-4306072-A | ANXIOLYTIC AND PSYCHOSTIMULANT ACTIVITY FOR TREATMENT OF PSYCHOLOGICAL DISORDERS | SOCIETE D'ETUDES SCIENTIFIQUES ET INDUSTRIELLES DE L'ILE (FR) | 1981-12-15 | — | — | US | disclosed |
| US-4268512-A | ANXIOLYTIC AGENTS, PSYCHOSTIMULANTS | SOCIETE D'ETUDES SCIENTIFIQUES ET INDUSTRIELLES DE L'ILE-DE-FRANCE (FR) | 1981-05-19 | — | — | US | disclosed |
| US-4255580-A | TREATMENT OF PSYCHOLOGICAL DISORDERS | SIOCIETE D'ETUDES SCIENTIFIQUES ET INDUSTRIELLES DE L'ILE-DE-FRANCE (FR) | 1981-03-10 | — | — | US | disclosed |
| US-4248885-A | FOR GASTROINTESTINAL, UROGENITAL, RHEUMATIC, AND CARDIOVASCULAR DISEASE | SOCIETE D'ETUDES SCIENTIFIQUES ET INDUSTRIELLES DE L'ILE-DE-FRANCE (FR) | 1981-02-03 | — | — | US | disclosed |
| US-4186135-A | TREATMENT OF PSYCHOLOGICAL DISORDERS | SOCIETE D'ETUDES SCIENTIFIQUES ET INDUSTRIELLES DE L'ILE-DE-FRANCE (FR) | 1980-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264429-A1 | Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders | XDH, CYP4X1, PDHX | ALDH1A1 313/4885KMT2A 1509/4885MEN1 2472/4885 |
| US-20090076274-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | XDH, CYP4X1, PDHX | ALDH1A1 736/4885KMT2A 1832/4885MEN1 1910/4885 |
| US-20100087483-A1 | Aminosulfonyl Substituted 4-(Aminomethyl)-Piperidine Benzamides As 5HT 4-Antagonists | HTR4, HTR2B, HTR2C | ALDH1A1 1067/4885KMT2A 478/4885MEN1 2258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.